Novartis AG has announced the commencement of a tender offer through its indirect wholly owned subsidiary, Redwood Merger Sub Inc., to acquire all outstanding shares of Regulus Therapeutics Inc. at $7.00 per share in cash, plus a contingent value right for an additional cash payment of $7.00 upon achieving a regulatory milestone. The offer, set in accordance with an Agreement and Plan of Merger dated April 29, 2025, will expire at one minute past 11:59 p.m. on June 24, 2025, unless extended or terminated earlier. Novartis has filed a tender offer statement with the SEC detailing the terms and conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.